ReShape Lifesciences Expects 2024 Operating Expenses Down 55.4% YoY
ReShape Lifesciences Expects 2024 Operating Expenses Down 55.4% YoY
ReShape Lifesciences預計2024年的運營支出同比下降55.4％
ReShape Lifesciences Expects 2024 Operating Expenses Down 55.4% YoY
ReShape Lifesciences預計2024年的運營支出同比下降55.4％
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。